Figure 6.

Neoadjuvant chemo-immunotherapy with MPAL suppressed the postsurgical metastasis and recurrence of B16–F10 tumors. (A) Schematic depicting the experimental procedure for evaluating postsurgical metastasis of B16–F10 tumors. (B) Individual tumor growth kinetics in PBS, MAL, and MPAL groups. (C) Mean tumor volume growth curves of mice in each group (Data are presented as mean ± SEM, ^∗∗∗P < 0.001: MPAL versus PBS). (D) Tumor weight of mice in each group on day 19 after second tumor inoculation. (E, F, and G) Flow cytometric analysis of CD4⁺ and CD8⁺ T cells in the spleen. (H) Schematic depicting the experimental procedure for evaluation of postsurgical recurrence of B16–F10 tumors. (I) Individual tumor growth curves in PBS, MAL, and MPAL groups after tumor rechallenged. (J) Mean tumor volume growth curves of mice in each group (Data are presented as mean ± SEM, ^∗P < 0.05). (K) Tumor weight of mice in each group on day 19 after tumor rechallenged. (L, M, and N) Flow cytometric analysis of central memory T cells (CD44⁺CD62L^low, T_CM) and effector memory T cells (CD44⁺CD62L^high, T_EM) in the spleen (gated on CD3⁺CD8⁺ T cells, n = 5). (^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001).